BEL-X not only shorten the treatment duration but also increase HBe seroconversion rate, and reduce viral rebound after stopping treatment of HBV patients.
The technologies of this project originates from national research institutes, and after more than 20 years of research and development, we have established six core technologies including cell biology, molecular biology, pharmacology and toxicology, clinical trial, pharmaceutical science, GACP agriculture, and patents. BEL-X will provide effective and safe treatment for patients in the future, and develop localized supply chain in response to the international situation, which will achieve medical independent and national security of health and safety.